NO20025064L - RGO koblet til peptider - Google Patents

RGO koblet til peptider

Info

Publication number
NO20025064L
NO20025064L NO20025064A NO20025064A NO20025064L NO 20025064 L NO20025064 L NO 20025064L NO 20025064 A NO20025064 A NO 20025064A NO 20025064 A NO20025064 A NO 20025064A NO 20025064 L NO20025064 L NO 20025064L
Authority
NO
Norway
Prior art keywords
rgo
peptides
linked
manufacture
compound
Prior art date
Application number
NO20025064A
Other languages
English (en)
Other versions
NO20025064D0 (no
Inventor
Marion De Jong
Eric Paul Krenning
Petrus Martinus Van Hagen
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of NO20025064D0 publication Critical patent/NO20025064D0/no
Publication of NO20025064L publication Critical patent/NO20025064L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20025064A 2000-04-26 2002-10-22 RGO koblet til peptider NO20025064L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201499 2000-04-26
PCT/EP2001/004764 WO2001081426A2 (en) 2000-04-26 2001-04-26 Rgd (arg-gly-asp) coupled to (neuro)peptides

Publications (2)

Publication Number Publication Date
NO20025064D0 NO20025064D0 (no) 2002-10-22
NO20025064L true NO20025064L (no) 2002-12-20

Family

ID=8171409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025064A NO20025064L (no) 2000-04-26 2002-10-22 RGO koblet til peptider

Country Status (15)

Country Link
US (1) US7202330B2 (no)
EP (2) EP1452543A3 (no)
JP (1) JP2004517034A (no)
AT (1) ATE272074T1 (no)
AU (2) AU6898201A (no)
CA (1) CA2407514C (no)
CZ (1) CZ20023539A3 (no)
DE (1) DE60104552T2 (no)
ES (1) ES2225570T3 (no)
HU (1) HUP0301571A2 (no)
IL (1) IL152466A0 (no)
NO (1) NO20025064L (no)
NZ (1) NZ522200A (no)
PL (1) PL202279B1 (no)
WO (1) WO2001081426A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20023539A3 (cs) 2000-04-26 2003-09-17 Biosynthema, Inc. Sloučeniny s vaznou afinitou pro alfa v beta3 - receptory a pro (neuro)peptidové receptory
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
CN100410276C (zh) 2003-03-31 2008-08-13 株式会社林原生物化学研究所 多肽
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
JP2009541302A (ja) 2006-07-24 2009-11-26 ザ プロクター アンド ギャンブル カンパニー シクロヘキセニルケトンのエピマー化方法及びアルドール縮合プロセスにおけるその利用
KR100987592B1 (ko) * 2008-03-10 2010-10-12 경북대학교 산학협력단 암진단용 ｍｒ 조영제와 그 제조방법
US9517201B2 (en) * 2008-04-04 2016-12-13 Rutgers, The State University Of New Jersey Nanocarrier and nanogel compositions
US8263133B2 (en) * 2009-02-18 2012-09-11 The Regents Of The University Of California Multivalent clustering targeting strategy for drug carriers
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
WO2014081655A1 (en) * 2012-11-21 2014-05-30 Serene Oncology, Llc Tin-1 17m comprising somatostatin receptor binding compounds
EP3568205B1 (en) 2017-01-12 2023-08-16 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
CN106967149A (zh) * 2017-05-04 2017-07-21 苏州强耀生物科技有限公司 一种棕榈酰化修饰的半胱氨酸多肽的制备方法
PL238941B1 (pl) * 2018-04-04 2021-10-25 Gdanski Univ Medyczny Związki chemiczne o działaniu przeciwuszkodzeniowym i/lub neuroprotekcyjnym
CN116510033B (zh) * 2023-03-09 2024-03-19 哈尔滨吉象隆生物技术有限公司 一种抗肿瘤的ppc药物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2878341B2 (ja) * 1989-03-03 1999-04-05 学校法人藤田学園 人工機能性ポリペプチド
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
CZ20023539A3 (cs) 2000-04-26 2003-09-17 Biosynthema, Inc. Sloučeniny s vaznou afinitou pro alfa v beta3 - receptory a pro (neuro)peptidové receptory

Also Published As

Publication number Publication date
CZ20023539A3 (cs) 2003-09-17
AU6898201A (en) 2001-11-07
PL357246A1 (en) 2004-07-26
AU2001268982B2 (en) 2006-06-15
WO2001081426A2 (en) 2001-11-01
ATE272074T1 (de) 2004-08-15
WO2001081426A3 (en) 2002-06-27
EP1452543A3 (en) 2005-08-03
PL202279B1 (pl) 2009-06-30
IL152466A0 (en) 2003-05-29
DE60104552D1 (de) 2004-09-02
EP1301540A2 (en) 2003-04-16
CA2407514A1 (en) 2001-11-01
JP2004517034A (ja) 2004-06-10
EP1301540B1 (en) 2004-07-28
EP1452543A2 (en) 2004-09-01
NO20025064D0 (no) 2002-10-22
HUP0301571A2 (hu) 2003-09-29
US20040136907A1 (en) 2004-07-15
DE60104552T2 (de) 2005-09-01
AU2001268982B8 (en) 2006-08-03
CA2407514C (en) 2011-03-29
ES2225570T3 (es) 2005-03-16
NZ522200A (en) 2004-07-30
US7202330B2 (en) 2007-04-10

Similar Documents

Publication Publication Date Title
NO20025064L (no) RGO koblet til peptider
EA200100464A1 (ru) Модифицированные пептиды как терапевтические агенты
DE69435105D1 (de) Derivate therapeutischer Peptide
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2001083525A3 (en) Modified peptides, comprising an fc domain, as therapeutic agents
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
CO5560528A2 (es) Agentes de contraste de objetivo multimetrico con base en peptidos
AR038568A1 (es) Anticuerpos anti-a beta y su uso
ATA14642003A (de) Impfstoff für die alzheimer-krankheit
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
DE60224508D1 (de) Wti-modifiziertes peptid
AR062867A2 (es) Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la
DZ3197A1 (fr) Acides aminés bicycliques utilises comme agents pharmaceutiques.
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
EE05139B1 (et) Peptiid, seda kodeeriv geen, reagent ja reaktiivikomplekt riketsioosi tuvastamiseks ning peptiidi sisaldav vaktsiin
AU7649098A (en) Syndecan interacting proteins and the use thereof
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2003029290A1 (fr) Transporteur de medicament et son utilisation
JP2002335964A5 (no)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application